Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment

← catalyst calendar

NCT07282093

Sponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →. With Guangzhou Healthquest Pharma Co., Ltd.

Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
48estimated
Sites
1
Country
China

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2025-11-11actualWhen the study began enrolling
Primary completion2026-06-30estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2026-10-31estimatedThe whole study's end, after follow-up
First posted2025-12-15actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-12-23actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Pharmacokinetic
  • Olverembatinib

Intervention

  • Drug: Olverembatinib 20mg

Primary outcomes

what the primary-completion date above is the date OF
Maximum observed plasma concentration C(max)
measured Day 1 to Day 9
Time to C(max) [ t(max) ]
measured Day 1 to Day 9
Apparent terminal elimination half-life (t½)
measured Day 1 to Day 9
Area under the concentration-time curve from time zero to last time of quantifiable concentration [AUC(last)]
measured Day 1 to Day 9
Area under the concentration-time curve from time zero to 192h AUC(0-192h)
measured Day 1 to Day 9
Apparent Clearance (CL/F)
measured Day 1 to Day 9
Apparent Volume of distribution (Vz/F)
measured Day 1 to Day 9
Unbound Fraction (fu)
measured Day 1 to Day 9

Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed